Related Experiment Videos
[Diode laser trans-scleral cyclo-photo-coagulation]
A Mańkowska1, Z Zagórski, P Kawa
1I Kliniki Okulistyki w Lublinie.
Klinika Oczna
|July 27, 1999
Summary
Diode laser transscleral cyclophotocoagulation (DLCT) effectively reduces intraocular pressure in refractory glaucoma patients. This safe treatment offers a viable option for advanced cases, with sustained IOP reduction over six months.
Area of Science:
- Ophthalmology
- Laser Surgery
Context:
- Glaucoma is a leading cause of irreversible blindness.
- Refractory glaucoma presents significant treatment challenges.
- Diode laser transscleral cyclophotocoagulation (DLCT) is an alternative surgical approach.
Purpose:
- To evaluate the efficacy and safety of DLCT for treating refractory glaucoma.
- To assess the reduction in intraocular pressure (IOP) post-DLCT.
Summary:
- 88 patients with refractory glaucoma underwent DLCT.
- Mean IOP decreased from 38.2 mmHg pre-treatment to 19.0 mmHg at 6 months.
- Treatment was repeated in 5.6% of patients; 2 experienced hypotony.
Impact:
- DLCT demonstrates a significant and sustained IOP reduction in refractory glaucoma.
- The procedure is relatively safe, with a low rate of complications like hypotony.
- This study supports DLCT as an effective treatment for advanced refractory glaucoma.